The glucocorticoid prednisolone successfully treated a man’s primary cold agglutinin disease (CAD), which is typically resistant to such therapies, a case report said. “Occasional” primary CAD cases “have demonstrated a favorable response” to glucocorticoids, “highlighting the need for a flexible and individualized therapeutic approach,” the researchers wrote. The case…
News
In people with cold agglutinin disease (CAD), pretreatment with Enjaymo (sutimlimab-jome) may limit disease-associated complications following urgent or planned surgeries in which a patient’s body temperature is considerably decreased. That’s according to a new report detailing the case of an 80-year-old woman in Japan for whom Enjaymo treatment before an…
A woman with cold agglutinin disease (CAD) developed an aggressive B-cell lymphoma after having only a brief response to Enjaymo (sutimlimab), according to a case report. Researchers said the “case highlights the importance of reassessing underlying conditions through [a bone marrow biopsy] in cases where [Enjaymo] treatment is…
A new tablet formulation of Annexon Biosciences’ experimental therapy ANX1502 resulted in therapy levels in the blood that surpassed those expected to be effective in fasting participants with cold agglutinin disease (CAD). These results from a proof-of-concept study reflect a promising pharmacokinetic profile, which describes how the medication…
Cold agglutinin disease (CAD) secondary to Mycoplasma pneumoniae (M. pneumoniae) infection in adults is linked to severe illness, including a high risk of complications related to blood clots and intensive care admissions, according to a national study in France. Still, data showed that most patients recover within weeks with…
A teenage girl in the U.K. was treated after developing cold agglutinin disease (CAD) as a rare complication of systemic lupus erythematosus (SLE), the most common form of the autoimmune disease lupus. CAD is a type of autoimmune hemolytic anemia (AIHA) that’s marked by immune attacks against red…
A dental infection triggered an attack of red blood cell destruction, or hemolysis, in a man in his 40s with cold agglutinin disease (CAD), according to a case report from Japan that, researchers say, highlights the need for CAD patients to maintain good oral hygiene. Previous studies have reported…
Treatment with rituximab — commonly used off-label for cold agglutinin disease (CAD) — was found to improve biomarkers of red blood cell destruction in people with CAD, but these benefits were often short-term and reversed within a few months, according to a real-world study in the U.S. The study also…
Thrombotic events (TE), or the blockage of blood flow due to blood clots, are relatively common among adults with cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA), according to a study in France. Researchers also found that experiencing five or more hemolytic attacks marked by…
Up to about 1 person in 100,000 in the U.S. is estimated to be diagnosed with primary cold agglutinin disease (CAD) each year and up to 3 in 10,000 people are living with the disease, a study that analyzed 2016-2023 data from national claim databases suggests. Primary CAD…
Recent Posts
- The life lessons I learned from frigid Friday night football games
- CAD study highlights need for more sensitive bone marrow testing
- Five things I do to have a positive patient experience
- Real-world data show Enjaymo reduces blood cell loss in CAD
- Diagnosis of primary CAD difficult with standard criteria: Study
- A crack emerges, leading to more CAD care for this antique
- Attending church can be challenging for this CAD patient
- Cell therapy helps woman with rare combination of 3 diseases
- National ‘That Sucks’ Day reminds me of all this weary CAD warrior endures
- Chemotherapy triggers cold agglutinin disease in woman with breast cancer